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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERCoronary Artery Calciﬁcation Review 1703
Mahesh V. Madhavan, Madhusudhan Tarigopula, Gary S. Mintz, Akiko Maehara,
Gregg W. Stone, Philippe Généreux
Madhavan and colleagues provide a broad overview of what is currently known about
coronary artery calciﬁcation (CAC). The pathogeneses of CAC and bone formation share
common pathways. Efforts to control CAC with medical therapy have not been successful.
Event-free survival is reduced in patients with CAC after both percutaneous coronary
intervention and bypass graft surgery. Innovative pharmacological and device-based
approaches are needed to improve the poor prognosis of patients with CAC.JACC WHITE PAPER JACC WHITE PAPERLone AF: Does it Exist? 1715
D. George Wyse, Isabelle C. Van Gelder, Patrick T. Ellinor, Alan S. Go, Jonathan M. Kalman,
Sanjiv M. Narayan, Stanley Nattel, Ulrich Schotten, Michiel Rienstra
The historical origin of the term “lone atrial ﬁbrillation” was meant to indicate atrial
ﬁbrillation (AF) in which subsequent investigations could not demonstrate heart disease.
As the list of heart diseases has expanded and diagnostic techniques have improved, the
prevalence of lone AF has fallen. Deﬁnitions of lone AF in the literature are inconsistent.
Guidelines provide a vague deﬁnition of lone AF, but do not provide direction about how
much or what kind of testing is necessary to exclude heart disease. The authors conclude that
the term “lone AF” is not useful in making treatment decisions and recommend that use of
the term “lone AF” be avoided.(continued on page A-30)
MAY 6, 2014 (continued) A-30CLINICAL RESEARCH CARDIOMETABOLIC RISKIL-1 Genetics, Oxidized Phospholipids, and CAD 1724
Sotirios Tsimikas, Gordon W. Duff, Peter B. Berger, John Rogus, Kenneth Huttner,
Paul Clopton, Emmanuel Brilakis, Kenneth S. Kornman, Joseph L. Witztum
Tsimikas and colleagues postulated that there would be an interaction between levels of
oxidized phospholipids, genetic variations in the interleukin (IL)-1 gene, and coronary
artery disease (CAD). IL-1 genotypes, oxidized phospholipids on apolipoprotein B-100
(OxPL/apoB), and lipoprotein(a) (Lp[a]) levels were measured in 499 patients undergoing
coronary angiography. The composite genotype termed IL-1(+) was deﬁned by 3 single
nucleotide polymorphisms in the IL-1 gene cluster associated with higher levels of pro-
inﬂammatory cytokines. Among IL-1(+) patients, the highest quartile of OxPL/apoB was
signiﬁcantly associated with a higher risk of CAD compared with the lowest quartile; there
was no relationship in IL-1() patients. These data suggest a clinically-relevant biological
link between pro-inﬂammatory IL-1 genotypes, oxidation of phospholipids, Lp(a), and
genetic predisposition to CAD and cardiovascular events.
Editorial Comment: Kausik K. Ray, p. 1735CARDIOMETABOLIC RISKArterial Stiffness, Cardiovascular Events, and Mortality 1739
Thomas T. van Sloten, Miranda T. Schram, Katja van den Hurk, Jacqueline M. Dekker,
Giel Nijpels, Ronald M. A. Henry, Coen D. A. Stehouwer
van Sloten and colleagues compared the predictive value of different arterial stiffness indexes
for cardiovascular disease and mortality in a population-based cohort. Local arterial stiffness
of carotid, femoral, and brachial arteries was assessed by ultrasonography, carotid-femoral
pulse wave velocity (cfPWV), aortic augmentation index, and systemic arterial compliance.
Hazard ratios for cardiovascular events and all-cause mortality were signiﬁcant for lower
carotid distensibility, higher carotid elastic modulus, lower carotid compliance, lower femoral
distensibility, lower femoral compliance, and higher cfPWV. Brachial stiffness, augmentation
index, and systemic arterial compliance were not associated with cardiovascular events or
mortality.
Editorial Comment: Athanase D. Protogerou, Theodoros G. Papaioannou,
Charalambos Vlachopoulos, p. 1748(continued on page A-36)
MAY 6, 2014 (continued) A-36HEART FAILUREPost-FDA Approval of HeartMate II as Destination Therapy 1751
Ulrich P. Jorde, Sudhir S. Kushwaha, Antone J. Tatooles, Yoshifumi Naka, Geetha Bhat,
James W. Long, Douglas A. Horstmanshof, Robert L. Kormos, Jeffrey J. Teuteberg, Mark S. Slaughter,
Emma J. Birks, David J. Farrar, Soon J. Park, for the HeartMate II Clinical Investigators
The U.S. Food and Drug Administration (FDA) required a post-approval (PA) study for
destination therapy (DT) to determine whether results with the HeartMate (HM) II left
ventricular assist device (LVAD) in a commercial setting are comparable to results from the
pivotal clinical trial (TR). The PA study was a prospective evaluation of the ﬁrst 247 HM II
patients identiﬁed pre-operatively as DT in the national INTERMACS (Interagency
Registry for Mechanically Assisted Circulatory Support) registry. Baseline characteristics
were similar for PA versus TR. Adverse events in the PA group were similar or lower than
TR, including improvements in stroke, device-related infection, and post-operative bleeding
requiring surgery. These ﬁndings support the original pivotal clinical trial ﬁndings regarding
the efﬁcacy and risk proﬁle of the HM II LVAD as DT.
Editorial Comment: Stavros G. Drakos, p. 1758HEART RHYTHM DISORDERSExtended Follow-Up of AF Rotor Ablation 1761
Sanjiv M. Narayan, Tina Baykaner, Paul Clopton, Amir Schricker, Gautam G. Lalani,
David E. Krummen, Kalyanam Shivkumar, John M. Miller
Narayan and colleagues found that the elimination of patient-speciﬁc rotor or focal atrial
ﬁbrillation (AF)–sustaining sources improved the short-term success of pulmonary vein
isolation procedures with conventional trigger ablation. Here, they report the 3-year
outcomes of the CONFIRM (Conventional Ablation for Atrial Fibrillation With or
Without Focal Impulse and Rotor Modulation) trial, which enrolled 92 consecutive AF
patients (71% persistent). Ablation consisted of focal impulse and rotor modulation (FIRM),
then conventional ablation (n ¼ 27) (FIRM-guided) and conventional ablation alone
(FIRM-blinded). FIRM-guided ablation patients maintained higher freedom from AF (78%
vs. 38%) and higher freedom from all atrial arrhythmias. These results show that FIRM-
guided ablation at patient-speciﬁc AF rotors and focal sources is more effective than
conventional trigger-based ablation at eliminating late as well as early arrhythmia recurrence.(continued on page A-37)
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Ayman A. Hussein, Ameer Abutaleb, Jean Jeudy, Timothy Phelan, Ronak Patel, Melsjan Shkullaku,
Faisal Siddiqi, Vincent See, Anastasios Saliaris, Stephen R. Shorofsky, Timm Dickfeld
In 2008, the U.S. Food and Drug Administration warned about potential interference of
computed tomography (CT) imaging with cardiac rhythm management (CRM) devices,
such as implantable cardioverter-deﬁbrillators (ICDs) or permanent pacemaker (PPMs).
Hussein and colleagues reviewed 516 CT scans that involved direct radiation exposure of
CRM devices at 2 large-volume centers. None of the CT imaging was associated with
signiﬁcant arrhythmias, nor did any result in the need for device removal or reprogramming.
With serial device interrogations, there were no differences in changes in battery voltage or
lead parameters between devices exposed to radiation and their controls. These ﬁndings
suggest that the presence of cardiac devices should not delay or result in cancellation of
clinically-indicated CT imaging procedures.
Editorial Comment: Elena Arbelo, Josep Brugada, p. 1776CARDIAC IMAGINGMyocardial Extracellular Remodeling in Congenital AS 1778
Susan M. Dusenbery, Michael Jerosch-Herold, Carsten Rickers, Steven D. Colan, Tal Geva,
Jane W. Newburger, Andrew J. Powell
Dusenbery and colleagues analyzed cardiac magnetic resonance (CMR) measurements of
myocardial extracellular volume fraction (ECV) and late gadolinium enhancement (LGE) in
children and young adults with congenital aortic stenosis (AS). The ECV was signiﬁcantly
higher in AS patients compared with control patients. LGE was present in 24% of the AS
patients. A higher ECV correlated with echocardiographic indexes of diastolic dysfunction.
In young patients with AS, myocardial ECV is signiﬁcantly elevated compared with control
patients and is associated with echocardiographic indexes of diastolic dysfunction.
Editorial Comment: Beth Feller Printz, p. 1786(continued on page A-38)
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Lieke J. J. Klinkenberg, Jan-Willem van Dijk, Frans E. S. Tan, Luc J. C. van Loon,
Marja P. van Dieijen-Visser, Steven J. R. Meex
Klinkenberg and colleagues tested whether chronically-elevated cardiac troponin T (cTnT)
levels ﬂuctuate randomly, ﬂuctuate predictably, or are stable throughout the day. Two studies
were conducted to investigate the presence of a diurnal rhythm of cTnT. Study 1 was
comprised of patients who had serial venous blood samples drawn over an 11-h period (8:30 AM
to 7:30 PM). In study 2, cTnT was measured hourly for 25 h. In the daytime study, there
was a gradual decrease in cTnT concentrations during the day (24  2%), which was present
in all participants. Study 2 also showed peak concentration during morning hours, gradually
decreasing values during day time, and rising concentrations during night time. These results
conﬁrm a diurnal rhythm in cTnT serum levels, with possible implications for the clinical
relevance of dynamic changes of cTnT levels.DISEASE OF THE AORTAImproved Outcomes for Acute Type A Aortic Dissection Repair With a
Multidisciplinary Team
1796Nicholas D. Andersen, Asvin M. Ganapathi, Jennifer M. Hanna, Judson B. Williams, Jeffrey G. Gaca,
G. Chad Hughes
Anderson and colleagues compared the results of acute type A aortic dissection (ATAAD)
repair before and after implementation of a multidisciplinary thoracic aortic surgery program
(TASP). The TASP included dedicated high-volume thoracic aortic surgeons, a
multidisciplinary approach to thoracic aortic disease management, and a standardized
protocol for ATAAD repair. Records of patients who underwent ATAAD repair before
(n ¼ 56) and after (n ¼ 72) implementation of the TASP were retrospectively compared.
Operative mortality fell from 34% before TASP implementation to 2.8% after TASP
implementation. These results suggest that ATAAD repair outcomes can be improved with
efforts to standardize and centralize the care of ATAAD patients.
Editorial Comment: D. Craig Miller, p. 1804
